Session » Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I
-
Abstract Number: 300
Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
-
Abstract Number: 301
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
-
Abstract Number: 303
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
-
Abstract Number: 304
Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance
-
Abstract Number: 305
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
-
Abstract Number: 306
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
-
Abstract Number: 307
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
-
Abstract Number: 308
Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
-
Abstract Number: 309
Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis
-
Abstract Number: 313
The DC-STAMP+IL17A+ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
-
Abstract Number: 314
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
-
Abstract Number: 316
Quantiferon-TB Test Can Be Usefull For Decision Of Anti-Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life
-
Abstract Number: 318
Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
-
Abstract Number: 321
Evaluation and Comparison Of Performance Of Different Classification Criteria For Reactive Arthritis
-
Abstract Number: 323
Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
-
Abstract Number: 324
Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
-
Abstract Number: 326
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
-
Abstract Number: 327
Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort – Results From An Exploratory Hierarchical Cluster Analysis
-
Abstract Number: 328
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
-
Abstract Number: 330
Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers
-
Abstract Number: 332
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
-
Abstract Number: 333
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
-
Abstract Number: 334
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
-
Abstract Number: 335
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
-
Abstract Number: 336
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
-
Abstract Number: 337
Fatigue and Work Disability In Psoriatic Arthritis
-
Abstract Number: 338
Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
-
Abstract Number: 339
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
-
Abstract Number: 340
Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis
-
Abstract Number: 341
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
-
Abstract Number: 342
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
-
Abstract Number: 343
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
-
Abstract Number: 344
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
-
Abstract Number: 347
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
-
Abstract Number: 349
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
-
Abstract Number: 350
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
-
Abstract Number: 351
Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review
-
Abstract Number: 352
Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis
-
Abstract Number: 353
Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets